Journal
INTERNATIONAL JOURNAL OF NEONATAL SCREENING
Volume 7, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ijns7040068
Keywords
neonatal screening; newborn screening; galactosemia; GALM; GALM deficiency
Categories
Ask authors/readers for more resources
The Leloir pathway metabolizes galactose and deficiencies in certain enzymes in this pathway are associated with genetic galactosemia. A new type of galactosemia, designated as type IV galactosemia, was recently discovered in patients with biallelic variants in the GALM gene upstream of GALK1. This relatively mild but not rare disease was identified through newborn screening in Japan.
The Leloir pathway, which consists of highly conserved enzymes, metabolizes galactose. Deficits in three enzymes in this pathway, namely galactose-1-phosphate uridylyltransferase (GALT), galactokinase (GALK1), and UDP-galactose-4 '-epimerase (GALE), are associated with genetic galactosemia. We recently identified patients with galactosemia and biallelic variants in GALM, encoding galactose epimerase (GALM), an enzyme that is directly upstream of GALK1. GALM deficiency was subsequently designated as type IV galactosemia. Currently, all the published patients with biallelic GALM variants were found through newborn screening in Japan. Here, we review GALM deficiency and describe how we discovered this relatively mild but not rare disease through the newborn screening system in Japan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available